Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare Inc (SRTS) delivers innovative superficial radiation therapy solutions for non-melanoma skin cancers and keloid treatment. This news hub provides investors and medical professionals with essential updates on the company's FDA-cleared devices, clinical advancements, and strategic partnerships.
Access timely updates on treatment protocol developments, technology enhancements, and market expansion initiatives. Our curated news collection features regulatory milestones, peer-reviewed study results, and operational updates directly impacting the dermatology and radiation oncology sectors.
Key focus areas include new device clearances, clinical efficacy data, partnership announcements with healthcare providers, and innovations in non-invasive treatment delivery. All content undergoes rigorous verification to ensure accuracy in reporting medical device developments.
Bookmark this page for consolidated access to SRTS's latest advancements in targeted radiation therapy. Return regularly for verified updates on this pioneering medical technology company's progress in transforming skin condition treatment protocols.
On April 25, 2023, Sensus Healthcare, Inc. (SRTS) announced a conference call scheduled for May 3, 2023, at 4:30 PM ET to discuss first-quarter 2023 financial results. During this call, management will also provide a business update and discuss ongoing and upcoming milestones. Participants can pre-register for the call to receive a unique dial-in number, allowing them to bypass the operator. The live webcast will be accessible through the company’s website, with a replay available until June 3, 2023. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, offering innovative devices for skin cancer and aesthetic procedures.
Sensus Healthcare (Nasdaq:SRTS) has launched Sensus Cloud, a groundbreaking cloud-based platform designed for asset and EMR management in healthcare. This platform allows healthcare providers to collect real-time data from medical devices, streamlining patient monitoring and treatment management.
Key features include an intuitive interface for tracking patient treatment history, device usage, and service details, alongside predictive analytics for proactive care management. The system ensures data security with multi-factor authentication and encryption, enhancing user and patient data protection. Sensus Healthcare will showcase this innovative platform at the American Academy of Dermatology Annual Meeting from March 17-19, 2023.
Sensus Healthcare reported a 65% increase in full-year revenues, totaling $44.5 million for 2022, driven by increased product demand. Fourth-quarter revenues reached $13.1 million, slightly up from $13.0 million year-over-year. However, net income fell to $2.8 million ($0.17 per share) compared to $5.3 million ($0.32 per share) in Q4 2021, largely due to rising manufacturing costs.
The company ended 2022 with $25.5 million in cash and no debt, with expectations of continued growth and a focus on expanding aesthetic product offerings in 2023.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on February 9, 2023, at 4:30 p.m. ET to discuss its financial results for Q4 and the full year 2022. The call will include a business update and insights on recent and upcoming milestones. Investors can access the call through a dial-in number or via a live webcast. A replay of the call will be available until March 9, 2023. Sensus specializes in non-invasive medical devices that utilize proprietary low-energy X-ray technology for treating oncological conditions, enhancing patient quality of life.
Sensus Healthcare (Nasdaq: SRTS) has announced key promotions and appointments within its management team to enhance growth and operational efficiency. Promoted to COO is Maggie Martinez, who has been with the company for nine years. Emiliano Sosa becomes CTO, focusing on engineering and technology expansion. Stephanie Tipton is now VP of Marketing, while Sean Delaney is appointed VP of Regulatory and Quality Assurance, and Wayne Lura becomes VP of Aesthetic Sales. These changes are part of Sensus' aggressive business strategy aimed at improving customer support and expanding market reach.
Sensus Healthcare, Inc. (SRTS) reports strong preliminary revenues for Q4 2022 expected to exceed $13 million and an estimated $44 million for the full year, marking 60% growth over 2021. The fourth quarter revenues will also include over $500,000 from the aesthetics segment. Profitability is expected for both the quarter and the year. Plans for 2023 include expanding the domestic sales force, increasing trade show presence, and geographic expansion in the EU and Latin America.
Sensus Healthcare (SRTS) reported a 64% increase in revenues to $9.0 million for Q3 2022, compared to $5.5 million in Q3 2021. Net income rose to $1.8 million or $0.11 per diluted share, up from $0.2 million or $0.01 per share a year earlier. The company exited Q3 with $37.6 million in cash and no debt. Adjusted EBITDA improved to $2.3 million from $0.5 million. Despite economic headwinds and Hurricane Ian's impact, Sensus expects continued growth and profitability for the fourth quarter.
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company focused on non-invasive treatments, will hold a conference call on November 3, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results. The call will include a business update and insights on recent and upcoming milestones. Interested participants can access the call via dial-in or through a live webcast. An archived replay will be available until December 3, 2022. Sensus specializes in superficial radiation therapy for treating non-melanoma skin cancers and keloids.
Sensus Healthcare announced the launch of its Silk™ hair removal system at the Fall Clinical Dermatology Conference in Las Vegas, running from October 20-23, 2022. This portable device features a 2000W diode laser with blended wavelengths, suitable for all skin types. The innovative system promises efficient energy distribution without disposable parts, reducing costs for both patients and practitioners. The Silk™ system is available in two modes: an 810nm single wavelength and a blend of four wavelengths for comprehensive treatment. CEO Joe Sardano emphasizes its efficacy and versatility.
